Successful Use of Sulbactam–Durlobactam in Treating Carbapenem-Resistant Acinetobacter baumannii Pneumonia and Sepsis After Liver Transplantation: A Case Report
American Journal of Case Reports · 2026
DOI: 10.12659/ajcr.949738 ↗Kurz gefasst
Fallbericht in der Zeitschrift American Journal of Case Reports, 2026. Verfasst von Hao-Feng Xiong und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Critical Liver Disease, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical Universi…. Hauptthemen laut MEDLINE: Acinetobacter baumannii, Acinetobacter Infections, Anti-Bacterial Agents, Pneumonia, Bacterial. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Sepsis
Abstract (Originalsprache)
BACKGROUND Orthotopic liver transplantation is the primary treatment for end-stage liver disease; however, postoperative infections, especially those caused by carbapenem-resistant Acinetobacter baumannii (CRAB), remain a major cause of mortality due to limited therapeutic options. Sulbactam-durlobactam (SUL-DUR), a novel b-lactam/b-lactamase inhibitor combination, has shown potent activity against CRAB. This report describes the first reported use of SUL-DUR in a liver transplant recipient with CRAB pneumonia and sepsis. CASE REPORT A 22-year-old woman with acute liver failure underwent auxiliary liver transplantation. Postoperatively, she developed CRAB pneumonia and septicemia confirmed by imaging, bronchoscopy, and metagenomic next-generation sequencing. She received combination therapy with SUL-DUR (1 g/1 g every 8 h), meropenem, eravacycline, and neutralized polymyxin B. Blood and sputum cultures confirmed CRAB susceptibility to SUL-DUR. Following treatment, inflammatory markers (CRP, IL-6, PCT) and pathogen loads markedly decreased, leading to complete clinical resolution without significant adverse effects. The patient was successfully discharged after rehabilitation. CONCLUSIONS SUL-DUR demonstrated excellent efficacy and safety in treating CRAB pneumonia and sepsis after liver transplantation. This case supports Phase III trial data and suggests the potential for use in high-risk, immunocompromised populations. Further studies are warranted to validate its clinical role and inform future guidelines for multidrug-resistant infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Critical Liver Disease, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Liver Transplantation Center, National Clinical Research Center for Digestive Diseases, Beijing Friendship Hospital, Capital Medical University, Beijing, China.
- Laboratory for Clinical Medicine, Capital Medical University, Beijing, China.
- Beijing Key Laboratory of Tolerance Induction and Organ Protection in Transplantation, Beijing, China.
ORCID-Profile: Hao-Feng Xiong, Wan-Ting Zhang, Fei Hou, Bang Liu, Ting-Ting Cui, Zhi-Ying He, Xin Zhang, Rui Zhao, Li-Ying Sun
Zitieren
APA
Xiong, H. F., Zhang, W. T., Liu, Y., Hou, F., Liu, B., Cui, T. T., He, Z. Y., Zhang, X., Zhao, R., & Sun, L. Y. (2026). Successful Use of Sulbactam–Durlobactam in Treating Carbapenem-Resistant Acinetobacter baumannii Pneumonia and Sepsis After Liver Transplantation: A Case Report. American Journal of Case Reports. https://doi.org/10.12659/ajcr.949738
Vancouver
Xiong HF, Zhang WT, Liu Y, Hou F, Liu B, Cui TT, et al. Successful Use of Sulbactam–Durlobactam in Treating Carbapenem-Resistant Acinetobacter baumannii Pneumonia and Sepsis After Liver Transplantation: A Case Report. American Journal of Case Reports. 2026. doi:10.12659/ajcr.949738
BibTeX
@article{Xiong2026,
author = {Xiong, Hao-Feng and Zhang, Wan-Ting and Liu, Ying and Hou, Fei and Liu, Bang and Cui, Ting-Ting and He, Zhi-Ying and Zhang, Xin and Zhao, Rui and Sun, Li-Ying},
title = {Successful Use of Sulbactam–Durlobactam in Treating Carbapenem-Resistant Acinetobacter baumannii Pneumonia and Sepsis After Liver Transplantation: A Case Report},
journal = {American Journal of Case Reports},
year = {2026},
doi = {10.12659/ajcr.949738}
}
EUVIMED